GBE1 (Gene)

Organism:

Homo sapiens

Synonyms:1,4-alpha-glucan branching enzyme 1, APBD, ENTREZ:2632, GBE, GBE1, GSD4, HGNC:4180, MIM:607839, NM_000158, NP_000149

Omim:OMIM:607839

Id:ENSG00000114480

Hgnc:HGNC:4180

Entrez:2632

Ensembl:ENSG00000114480

Description:1,4-alpha-glucan branching enzyme 1

The protein encoded by this gene is a glycogen branching enzyme that catalyzes the transfer of alpha-1,4-linked glucosyl units from the outer end of a glycogen chain to an alpha-1,6 position on the same or a neighboring glycogen chain. Branching of the chains is essential to increase the solubility of the glycogen molecule and, consequently, in reducing the osmotic pressure within cells. Highest level of this enzyme are found in liver and muscle. Mutations in this gene are associated with glycogen storage disease IV (also known as Andersen's disease). [provided by RefSeq, Jul 2008]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View GBE1's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with GBE1.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using GBE1.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for GBE1.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GBE1.

Results found

Linked to

	Label	Description
	GSE225869 1 V 0 TEMOZOLOMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE226249 pirfenidone HL 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE203362 0 V 1 ENZALUTAMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE96649 1 V 0 DEXAMETHASONE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE233679 12 V 0 NICOTINAMIDE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE120370 0 V 6 THROMBIN MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE120612 4 V 1 ETOPOSIDE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE168401 2 V 0 HARMINE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE169356 ivermectin prostate gland 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE95077 1 V 2 AMILORIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS

GSE225869 1 V 0 TEMOZOLOMIDE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE226249 pirfenidone HL 2 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE203362 0 V 1 ENZALUTAMIDE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE96649 1 V 0 DEXAMETHASONE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE233679 12 V 0 NICOTINAMIDE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE120370 0 V 6 THROMBIN MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE120612 4 V 1 ETOPOSIDE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE168401 2 V 0 HARMINE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE169356 ivermectin prostate gland 0 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE95077 1 V 2 AMILORIDE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.